Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Romano

Showing results (91-100 of 165) with videos related to

Pageof 17
Sort By:
Cancers|March 10, 2022
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 InfectionAlessandra Romano, Claudio Cerchione, Concetta Conticello, et al.
European Journal of Haematology|November 24, 2025
Hodgkin-Inflammatory-Based Model ME-IPS Is a New Inflammatory-Based Prognostic Model Calculated at Diagnosis: Results From a Real-Life StudyAndrea Duminuco, Vittorio Del Fabro, Gabriella Santuccio, et al.
Expert Review of Molecular Diagnostics|May 1, 2018
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapyAlessandra Romano, Nunziatina Laura Parrinello, Piera La Cava, et al.
Oncotarget|March 12, 2016
Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)Cesarina Giallongo, Daniele Tibullo, Nunziatina L Parrinello, et al.
Leukemia Research|August 3, 2010
NF-κB localization in multiple myeloma plasma cells and mesenchymal cellsConcetta Conticello, Raffaella Giuffrida, Luana Adamo, et al.
Journal of Clinical Medicine|October 19, 2019
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsMarina Silvia Parisi, Salvatore Leotta, Alessandra Romano, et al.
Cell Death & Disease|October 30, 2019
Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myelomaCesarina Giallongo, Daniele Tibullo, Giuseppina Camiolo, et al.
Clinical and Experimental Medicine|June 27, 2024
Comprehensive analysis of clinical outcomes, infectious complications and microbiological data in newly diagnosed multiple myeloma patients: a retrospective observational study of 92 subjectsVanessa Desantis, Paola Borrelli, Teresa Panebianco, et al.
Cell Death & Disease|September 22, 2019
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myelomaCesarina Giallongo, Daniele Tibullo, Giuseppina Camiolo, et al.
Biomolecules|January 22, 2021
Focus on Osteosclerotic Progression in Primary MyelofibrosisMariarita Spampinato, Cesarina Giallongo, Alessandra Romano, et al.
Pageof 17

Showing results (91-100 of 165) with videos related to

Sort By:
Pageof 17
Cancers|March 10, 2022
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 InfectionAlessandra Romano, Claudio Cerchione, Concetta Conticello, et al.
European Journal of Haematology|November 24, 2025
Hodgkin-Inflammatory-Based Model ME-IPS Is a New Inflammatory-Based Prognostic Model Calculated at Diagnosis: Results From a Real-Life StudyAndrea Duminuco, Vittorio Del Fabro, Gabriella Santuccio, et al.
Expert Review of Molecular Diagnostics|May 1, 2018
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapyAlessandra Romano, Nunziatina Laura Parrinello, Piera La Cava, et al.
Oncotarget|March 12, 2016
Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)Cesarina Giallongo, Daniele Tibullo, Nunziatina L Parrinello, et al.
Leukemia Research|August 3, 2010
NF-κB localization in multiple myeloma plasma cells and mesenchymal cellsConcetta Conticello, Raffaella Giuffrida, Luana Adamo, et al.
Journal of Clinical Medicine|October 19, 2019
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsMarina Silvia Parisi, Salvatore Leotta, Alessandra Romano, et al.
Cell Death & Disease|October 30, 2019
Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myelomaCesarina Giallongo, Daniele Tibullo, Giuseppina Camiolo, et al.
Clinical and Experimental Medicine|June 27, 2024
Comprehensive analysis of clinical outcomes, infectious complications and microbiological data in newly diagnosed multiple myeloma patients: a retrospective observational study of 92 subjectsVanessa Desantis, Paola Borrelli, Teresa Panebianco, et al.
Cell Death & Disease|September 22, 2019
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myelomaCesarina Giallongo, Daniele Tibullo, Giuseppina Camiolo, et al.
Biomolecules|January 22, 2021
Focus on Osteosclerotic Progression in Primary MyelofibrosisMariarita Spampinato, Cesarina Giallongo, Alessandra Romano, et al.
Pageof 17